Small Pharma Inc. (DMTTF) Research

Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder. Specifically, its compound SPL026 is currently in Phase IIA clinical trials for MDD treatment. The company's preclinical pipeline also includes SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. Founded in 2015, Small Pharma Inc. is headquartered in London, United Kingdom.

Market snapshot

Symbol
DMTTF
Price
$0.11
Day change
-9.69%
Market cap
$53.2M
P/E ratio
-2.23x
52-week range
0.045-0.1905
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Alpha Cognition Inc. (ACOGF)
  • China Shineway Pharmaceutical Group Limited (CSWYY)
  • Enzo Biochem, Inc. (ENZB)
  • IntelGenx Technologies Corp. (IGXT)
  • ImmuPharma plc (IMMPF)
  • LakeShore Biopharma Co., Ltd (LSBCF)
  • Medivir AB (publ) (MVRBF)
  • Abliva AB (publ) (NEVPF)

Open Small Pharma Inc. (DMTTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.